FDA: Spiriva HandiHaler doesn't increase stroke or heart risks

01/14/2010 | Wall Street Journal, The

The FDA concluded that clinical data show no concrete evidence that Spiriva HandiHaler heightens the risk of stroke or cardiovascular problems in patients with chronic obstructive pulmonary disease. The product, which is owned by Boehringer Ingelheim and Pfizer, underwent a government investigation in 2008 because of stroke concerns.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY